US EditionGLIX1 named FDA orphan drug for treatment of malignant glioma
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
GLIX1 named FDA orphan drug for treatment of malignant glioma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GLIX1, a cancer treatment now in the preclinical stages of development, as a potential therapy for malignant glioma, its developer Hemispherian announced. GLIX1 is designed to kill cancer cells by going after the cells’ DNA. The FDA awards orphan drug status to investigational therapies that have the potential to treat disorders that affect fewer than 200,000 peop…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
